These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1114 related items for PubMed ID: 27116120

  • 1. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
    Takashina T, Kinoshita I, Kikuchi J, Shimizu Y, Sakakibara-Konishi J, Oizumi S, Nishimura M, Dosaka-Akita H.
    Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
    [Abstract] [Full Text] [Related]

  • 2. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
    Kikuchi J, Takashina T, Kinoshita I, Kikuchi E, Shimizu Y, Sakakibara-Konishi J, Oizumi S, Marquez VE, Nishimura M, Dosaka-Akita H.
    Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
    [Abstract] [Full Text] [Related]

  • 3. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H, Li Y, Yuan Y, Li W, Zhang H, Zhang Z, Shi R, Liu M, Liu C, Chen C, Liu H, Chen J.
    BMC Cancer; 2020 Dec 04; 20(1):1189. PubMed ID: 33276757
    [Abstract] [Full Text] [Related]

  • 4. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.
    Fiskus W, Rao R, Balusu R, Ganguly S, Tao J, Sotomayor E, Mudunuru U, Smith JE, Hembruff SL, Atadja P, Marquez VE, Bhalla K.
    Clin Cancer Res; 2012 Nov 15; 18(22):6227-38. PubMed ID: 22932665
    [Abstract] [Full Text] [Related]

  • 5. The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.
    Chen MC, Chen CH, Wang JC, Tsai AC, Liou JP, Pan SL, Teng CM.
    Cell Death Dis; 2013 Sep 19; 4(9):e810. PubMed ID: 24052078
    [Abstract] [Full Text] [Related]

  • 6. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
    Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, Ustun C, Rao R, Fernandez P, Chen J, Balusu R, Koul S, Atadja P, Marquez VE, Bhalla KN.
    Blood; 2009 Sep 24; 114(13):2733-43. PubMed ID: 19638619
    [Abstract] [Full Text] [Related]

  • 7. Antitumor effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid in epidermal growth factor receptor-mutant non-small-cell lung cancer lines in vitro and in vivo.
    Wei Y, Zhou F, Lin Z, Shi L, Huang A, Liu T, Yu D, Wu G.
    Anticancer Drugs; 2018 Mar 24; 29(3):262-270. PubMed ID: 29356692
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo.
    Singh T, Prasad R, Katiyar SK.
    Epigenetics; 2013 Jan 24; 8(1):54-65. PubMed ID: 23221619
    [Abstract] [Full Text] [Related]

  • 9. Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.
    Savickiene J, Treigyte G, Valiuliene G, Stirblyte I, Navakauskiene R.
    Anticancer Drugs; 2014 Sep 24; 25(8):938-49. PubMed ID: 24800886
    [Abstract] [Full Text] [Related]

  • 10. Novel histone deacetylase inhibitors derived from Magnolia officinalis significantly enhance TRAIL-induced apoptosis in non-small cell lung cancer.
    Liu Y, Tong Y, Yang X, Li F, Zheng L, Liu W, Wu J, Ou R, Zhang G, Hu M, Liu Z, Lu L.
    Pharmacol Res; 2016 Sep 24; 111():113-125. PubMed ID: 27268146
    [Abstract] [Full Text] [Related]

  • 11. Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells.
    Valiulienė G, Stirblytė I, Jasnauskaitė M, Borutinskaitė V, Navakauskienė R.
    Eur J Pharmacol; 2017 Mar 15; 799():143-153. PubMed ID: 28192098
    [Abstract] [Full Text] [Related]

  • 12. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
    Fiskus W, Pranpat M, Balasis M, Herger B, Rao R, Chinnaiyan A, Atadja P, Bhalla K.
    Mol Cancer Ther; 2006 Dec 15; 5(12):3096-104. PubMed ID: 17172412
    [Abstract] [Full Text] [Related]

  • 13. Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma.
    Yamaguchi J, Sasaki M, Sato Y, Itatsu K, Harada K, Zen Y, Ikeda H, Nimura Y, Nagino M, Nakanuma Y.
    Cancer Sci; 2010 Feb 15; 101(2):355-62. PubMed ID: 19860841
    [Abstract] [Full Text] [Related]

  • 14. Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.
    Shi B, Behrens C, Vaghani V, Riquelme EM, Rodriguez-Canales J, Kadara H, Lin H, Lee J, Liu H, Wistuba I, Simon G.
    Cancer Med; 2019 Oct 15; 8(14):6383-6392. PubMed ID: 31456359
    [Abstract] [Full Text] [Related]

  • 15. Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.
    Wang Y, Chen SY, Colborne S, Lambert G, Shin CY, Santos ND, Orlando KA, Lang JD, Hendricks WPD, Bally MB, Karnezis AN, Hass R, Underhill TM, Morin GB, Trent JM, Weissman BE, Huntsman DG.
    Mol Cancer Ther; 2018 Dec 15; 17(12):2767-2779. PubMed ID: 30232145
    [Abstract] [Full Text] [Related]

  • 16. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFRL858R/T790M mutation.
    Wang G, Zhao J, Zhang M, Wang Q, Chen B, Hou Y, Lu K.
    Int J Nanomedicine; 2019 Dec 15; 14():4503-4515. PubMed ID: 31417255
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
    Yu W, Lu W, Chen G, Cheng F, Su H, Chen Y, Liu M, Pang X.
    Br J Pharmacol; 2017 Oct 15; 174(20):3608-3622. PubMed ID: 28749535
    [Abstract] [Full Text] [Related]

  • 18. EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells.
    Katona BW, Liu Y, Ma A, Jin J, Hua X.
    Cancer Biol Ther; 2014 Oct 15; 15(12):1677-87. PubMed ID: 25535899
    [Abstract] [Full Text] [Related]

  • 19. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G, Knievel J, Koch A, Hader C, Fischer U, Albers P, Schulz WA.
    Urol Oncol; 2013 Nov 15; 31(8):1770-9. PubMed ID: 22944197
    [Abstract] [Full Text] [Related]

  • 20. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
    Kim JS, Lee SC, Min HY, Park KH, Hyun SY, Kwon SJ, Choi SP, Kim WY, Lee HJ, Lee HY.
    Cancer Lett; 2015 Jun 01; 361(2):197-206. PubMed ID: 25721083
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.